Jacob P. Laubach

ORCID: 0000-0001-7565-2052

Also affiliated with Dana-Farber Cancer Institute

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma”.

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

New England Journal of Medicine(2022)10.1056/nejmoa2204925

N/A

6.2DataRank · unranked

474 citations

Susanna Jacobus, Edie Weller, Hani Hassoun, Sagar Lonial, Noopur Raje +51 more

A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)

American Journal of Hematology(2021)10.1002/ajh.26361

N/A

0.994DataRank · unranked

23 citations

Vera J. Suman, Sascha A. Tuchman, Jacob P. Laubach, Hani Hassoun, Yvonne A. Efebera +7 more

Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins

Cell Reports(2021)10.1016/j.celrep.2020.108532

N/A

0.716DataRank · unranked

117 citations

Geoffrey M. Matthews, Sara Gandolfi, Ricardo De Matos Simoes, Dennis L. Buckley, Joseline Raja +34 more

Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma

Cancer Cell(2022)10.1016/j.ccell.2022.10.017

N/A

0.626DataRank · unranked

64 citations

Michelle P. Aranha, Robert Redd, Joanna Bagińska, Nicholas J. Haradhvala, Margaret Hallisey +34 more

Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse

Blood Advances(2024)10.1182/bloodadvances.2024013623

N/A

0.372DataRank · unranked

5 citations

Vera J. Suman, Yvonne A. Efebera, Noopur Raje, Sascha A. Tuchman, Cesar Rodriguez Valdes +7 more

Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone

medRxiv(2024)10.1101/2024.04.19.24306082

N/A

0.343DataRank · unranked

6 citations

Michelle P. Aranha, Robert Redd, Michael Timonian, Sophie Magidson, Elizabeth D. Lightbody +17 more

Single-cell and clonal analysis of AL amyloidosis plasma cells and their bone marrow microenvironment

Blood(2025)10.1182/blood.2024024719

N/A

0DataRank · unranked

2 citations

Maria Moscvin, Matteo Da Vià, Francesca Lazzaroni, Alice Nevone, Sam Sadigh +20 more

Clinical Outcomes of Monoclonal Gammopathy of Renal Significance Without Detectable Clones

Kidney International Reports(2023)10.1016/j.ekir.2023.09.022

N/A

0DataRank · unranked

9 citations

Umut Selamet, Shonali Midha, Omar Nadeem, Jacob P. Laubach, Helmut G. Rennke +2 more

Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial

Nature Communications(2025)10.1038/s41467-024-55308-5

N/A

0DataRank · unranked

14 citations

Michelle P. Aranha, Robert Redd, Michael Timonian, Sophie Magidson, Elizabeth D. Lightbody +17 more

Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression

Journal of Clinical Oncology(2020)10.1200/jco.20.00437

N/A

0DataRank · unranked

182 citations

Romanos Sklavenitis‐Pistofidis, Jihye Park, Robert Redd, Benny Zhitomirsky, Andrew Dunford +31 more